# In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma

> **NCT07715630** · PHASE1 · RECRUITING · sponsor: **Chongqing Precision Biotech Co., Ltd** · enrollment: 15 (estimated)

## Conditions studied

- Relapsed or Refractory Multiple Myeloma (RRMM)

## Interventions

- **BIOLOGICAL:** Invivo CAR-T

## Key facts

- **NCT ID:** NCT07715630
- **Lead sponsor:** Chongqing Precision Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-31
- **Primary completion:** 2028-04-30
- **Final completion:** 2028-07-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07715630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07715630, "In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07715630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*